Study of Apatinib as an Inhibitor of Tumor Angiogenesis
NCT00633490
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
18
Enrollment
OTHER
Sponsor class
Conditions
Tumor
Interventions
DRUG:
apatinib
Sponsor
Fudan University